PI CME: Seizure Frequency Process and Outcome: Standardizing Capture of Seizure Frequency, Type, and Time Since Last Seizure
Availability
On-Demand
3 Courses
Cost
Member: $149.99
Non-Member: $299.99
Credit Offered
20 CME Credits
20 CC Credits
Provided by the American Epilepsy Society
Release Date: August 26, 2026
Expiration Date: August 25, 2029
Primarily neurologists, epileptologists, advanced practice providers, and others responsible for prescribing in clinic.

This web-based activity is designed to help you assess and enhance your current practices in documenting seizure frequency, type, and time since last seizure for patients with epilepsy in a clinical setting. The primary goal of this performance improvement project is to establish or refine a standardized process for capturing and documenting key seizure activity parameters—seizure type, seizure frequency, and time since last seizure—for all patients with a primary diagnosis of epilepsy.

Please be aware this activity will take at least 32 days to complete. After completing all learning material in Stage B, the learner should implement the learned interventions into practice over the next 30 days. After 30 days, the learner will have access to Stage C, which will measure the success of the interventions.

The activity consists of three stages:

  1. Stage A: Conduct a quality improvement evaluation by reviewing ten patient charts. Use the proposed quality metrics to assess current documentation of seizure type, seizure frequency, and time since last seizure. Reflect on your findings.
  2. Stage B: Based on Stage A results, develop and implement a plan to optimize the clinical process for documenting seizure frequency, type, and time since last seizure. This plan should aim to improve documentation accuracy, consistency, and workflow integration.
  3. Stage C: Assess the impact of your intervention by reviewing ten new patient charts (seen after implementing Stage B). Utilize the quality metrics from Stage A to evaluate improvements in documentation of seizure type, seizure frequency, and time since last seizure.

For additional details on activity objectives, rationale, process, and example metrics, refer to the slide set: Performance Improvement Project: Seizure Frequency Process and Outcome

Following completion of this activity, the learner should able to:
  1. Standardize Seizure Documentation - Implement a standardized process for capturing seizure type, seizure frequency, and time since last seizure for all patients with a primary diagnosis of epilepsy.
  2. Apply Evidence-Based Classification Systems – Utilize AAN/LOINC standardized seizure type categories and frequency descriptors to ensure consistent and clinically meaningful documentation across visits.
  3. Identify Barriers and Solutions – Recognize common barriers to seizure documentation (e.g., patient/caregiver unavailability, lack of standardized tools) and apply strategies to address them, including EHR-based tools and patient education.
  4. Improve Patient Outcomes – Understand how consistent documentation of seizure activity parameters supports clinical decision-making, including medication titration, surgical candidacy evaluation, SUDEP risk assessment, driving determinations, and quality-of-life outcomes.
  5. Engage Patients and Caregivers – Provide education to patients and caregivers on how to describe and report seizure frequency and type, including the use of seizure diaries, tracking devices, and video documentation.
In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with commercial interests have been mitigated. The following individuals contributed to this activity’s content.

Faculty/Authors 

Deepti Zutshi, MD

Alexandria Melendez-Zaidi, MD

Jorge Marcos, MD

Jonathan Williams, MD

Brandy Fureman, PhD

Barbara Decker, MD 

Planners 

Deepti Zutshi, MD

Alexandria Melendez-Zaidi, MD

Jorge Marcos, MD

Jonathan Williams, MD

Brandy Fureman, PhD

Barbara Decker, MD 

Lauren Orciuoli, MBAH, MPH

AES Staff 
Lauren Orciuoli, MBAH, MPH, AES Senior Manager, Clinical Activities
Melissa Ball, CAE, CHCP, PMP Senior Manager, Online Education
AES Staff involved in this activity have indicated they have no financial relationships to disclose relevant to this activity. 

CME Reviewer

Shahram Izadyar MD, FAES
The American Epilepsy Society designates this enduring material activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

International Credits: The American Medical Association has determined that non-US. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 20 hours of Category 1 credit for completing this program.
The American Board of Psychiatry and Neurology has reviewed the PI-CME activity "Seizure Frequency Process and Outcome: Standardizing Capture of Seizure Frequency, Type, and Time Since Last Seizure" and has approved this program as part of a comprehensive Improvement in Medical Practice (PIP) program, which is mandated by the ABMS as a necessary component of continuing certification. For more information about Continuing Certification, please contact the American Board of Psychiatry and Neurology directly.

Resolution of Conflicts of Interest 

It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Unapproved Use Disclosure 

The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity. 

Contact Information 

For further information on this activity contact the American Epilepsy Society at education@aesnet.org or call 312.883.3800. 

Privacy and Confidentiality 

The American Epilepsy Society respects the privacy and confidentiality of users of this CME activity. You may access the privacy statement for this activity here 

Policy on Commercial Support and Conflict of Interest 

As an ACCME-accredited provider the American Epilepsy Society must ensure 100% compliance with the ACCME Standards for Commercial Support: Standards to Ensure Independence in CME Activities. The American Epilepsy Society has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. 

Disclosure of Unlabeled/Unapproved Uses 

This educational activity may include references to the use of products for indications not approved by the FDA. Faculty have agreed to disclose intent to discuss any off-label, experimental, or investigational use of drugs, devices, or equipment or devices in their presentations.  Furthermore, faculty have attested that all the recommendations involving clinical medicine they make in this activity will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; and, all scientific research referred to, reported, or used in their presentation in support or justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection and analysis.  Faculty opinions expressed with regard to unapproved, investigational or experimental uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society. 

Disclaimer 

This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses. 

Powered By